8-K: Tenax Therapeutics Amends Executive Employment Agreements

Tenax Therapeutics, Inc. has amended employment agreements for key executives, establishing severance and change-in-control benefits.

Summary

• Tenax Therapeutics, Inc. announced on June 26, 2026, that its Board of Directors approved amendments to the employment agreements for Christopher Giordano, Thomas Staab, and Stuart Rich.
• These amendments align severance and change-in-control benefits for these executives with the newly adopted Tenax Therapeutics, Inc. Change in Control Plan (CIC Plan) and Tenax Therapeutics, Inc. Severance Plan.
• Benefits are contingent upon the execution of a release of claims.
• In case of termination without Cause or non-renewal by the Company (not related to a Change in Control), executives are entitled to 12 months of base salary plus an additional month per year of service (up to 12 additional months), a pro-rated annual bonus, and 12 months of COBRA reimbursements.
• Dr. Rich will also receive accelerated vesting of all outstanding equity awards in such termination scenarios.
• In the event of termination without Cause, by the executive for Good Reason, or non-renewal during the three months prior to or 12 months following a Change in Control, executives will receive 12 months of base salary (18 months for Mr. Giordano), the full annual bonus, accelerated vesting of all equity awards, and 12 months of COBRA reimbursements (18 months for Mr. Giordano).
• The Company also adopted the CIC Plan and Severance Plan on June 26, 2026.
• The CIC Plan offers double trigger equity acceleration and cash severance for eligible employees upon a change in control, payable upon termination without Cause or by the employee for Good Reason.
• The Severance Plan provides severance benefits for terminations by the Company without Cause, independent of a change in control, with benefits based on tenure and level.
• Executive officers are not eligible for the CIC Plan or Severance Plan but are covered by their amended individual employment agreements.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It addresses standard corporate governance and executive compensation matters without presenting significant positive or negative financial news.

Positives

• Provides enhanced severance and change-in-control benefits for key executives, potentially aiding retention and stability during transitions.
• Adoption of formal Change in Control and Severance Plans creates a more structured and predictable framework for executive and employee compensation during specific events.
• The plans offer 'double trigger' equity acceleration, meaning both a change in control and a qualifying termination are required, which is generally viewed favorably as it protects against involuntary job loss following a merger.
• The amended agreements ensure that key executives receive benefits generally aligned with the new company-wide plans.

Negatives

• The specific details of the 'level' and 'tenure' used to calculate severance benefits under the Severance Plan are not fully detailed in this filing, making precise quantification difficult.
• The executive officers are explicitly excluded from the new company-wide CIC and Severance Plans, relying solely on their individual amended agreements, which could be perceived as creating a tiered system.

Risks

• The effectiveness of these plans in retaining key personnel during uncertain times or potential acquisition scenarios remains to be seen.
• The definition of 'Cause' and 'Good Reason' within the agreements and plans are critical and could lead to disputes if not clearly defined and consistently applied.

Future Outlook

The filing does not contain specific forward-looking financial guidance. The focus is on executive compensation and severance arrangements, which are designed to provide stability and incentives for management during potential corporate events.

Management Comments

• The amendments to the employment agreements provide severance and other benefits that are generally based on the severance and change in control benefits that each such executive would be eligible to receive under the CIC Plan and the Severance Plan, as applicable.
• The CIC Plan provides double trigger equity acceleration and cash severance benefits to eligible employees of the Company in connection with a change in control transaction.
• The Severance Plan provides severance benefits to eligible employees of the Company whose employment is terminated by the Company without Cause, independent of any change in control transaction.

Industry Context

StockSavvy.ai notes that the adoption of formal Change in Control and Severance Plans, along with amendments to executive employment agreements, is a common practice in the biotechnology and pharmaceutical sectors, particularly for companies that may be acquisition targets or are undergoing significant strategic shifts. These measures are often implemented to ensure management continuity and alignment during periods of potential transition or uncertainty.

Corporate Governance

Stakeholder Impact

• Shareholders: The amendments and new plans provide clarity on executive compensation and severance, which can contribute to stability and reduce uncertainty during potential change-in-control events. However, the cost of these benefits will impact the company's overall compensation expenses.
• Employees: Eligible employees will benefit from the new Severance Plan and CIC Plan, providing a safety net in case of termination without Cause or following a change in control.
• Executives: Christopher Giordano, Thomas Staab, and Stuart Rich will receive enhanced and clarified severance and change-in-control benefits under their amended employment agreements.

Next Steps

• Executives are required to execute a release of claims to receive benefits under the amended employment agreements.
• The CIC Plan and Severance Plan will govern future severance and change-in-control benefits for eligible employees.
• The company will continue to operate under its existing structure until any change in control or termination events occur.

Key Dates

Keywords

Tenax Therapeutics, 8-K, Executive Employment Agreement, Severance Plan, Change in Control Plan, Christopher Giordano, Thomas Staab, Stuart Rich, Compensation, Equity Acceleration, SEC Filing